Drug Type Small molecule drug |
Synonyms- |
Action inhibitors, stimulants |
Mechanism NLRP3 inhibitors(NACHT, LRR and PYD domains-containing protein 3 inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors), SIRT1 stimulants(NAD-dependent deacetylase sirtuin 1 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Inflammatory Bowel Diseases | Preclinical | China | 01 Dec 2025 | |
| Inflammatory Bowel Diseases | Preclinical | China | 01 Dec 2025 | |
| Lung Injury | Preclinical | China | 01 Aug 2025 |





